Evidence map›Paper›PMID 42015349›Full record

ArticleCancer biology & therapy2026

Real-world efficacy of Bruton tyrosine kinase inhibitor based maintenance therapy in diffuse large B-cell lymphoma: a multicenter retrospective cohort study with external historical control.

Li-Wei Lyu, Na Yao, Zi-Xian Liu, Yan-Ying Wang, Jie Li, He-Bing Zhou, Li-Hong Li, Zhen-Ling Li, Liang Wang

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Li-Wei LyuDepartment of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Na YaoDepartment of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Zi-Xian LiuDepartment of Hematology, China-Japan Friendship Hospital, Beijing, China.
Yan-Ying WangDepartment of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Jie LiDepartment of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
He-Bing ZhouDepartment of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Li-Hong LiDepartment of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Zhen-Ling LiDepartment of Hematology, China-Japan Friendship Hospital, Beijing, China.
Liang WangDepartment of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-3995-9097

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe selection of an optimal maintenance agent in diffuse large B-cell lymphoma (DLBCL) continues to pose a significant clinical challenge. This study aims to evaluate the prognostic impact of maintenance therapy (MT) in DLBCL.

methodsWe conducted a retrospective analysis of data from DLBCL patients undergoing first-line MT at four hospitals in Beijing between January 2019 and August 2024. The REMoDL-B trial database was selected as the control group.

resultsThe MT group comprised 106 cases and a median follow-up duration of 25.4 months. The rates of progression and death were 11.32% (12/106) and 1.89% (2/106), respectively. The 2-y progression-free survival (PFS) and overall survival (OS) rates were 90% and 98%, respectively. The MT group demonstrated significantly superior PFS and OS compared to the control group (

conclusionsWhile limited by the retrospective study, our analysis raises the hypothesis that MT may correlate with improved DLBCL outcomes. A similar trend suggesting potential benefit from BTKi maintenance was noted, meriting further investigation in controlled settings.

Indexed as

Agammaglobulinaemia Tyrosine KinaseAntineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseMaintenance ChemotherapyProtein Kinase InhibitorsAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesAgammaglobulinaemia Tyrosine KinaseBTK protein, humanProtein Kinase InhibitorsBTKicentral nervous systemDiffuse large B-cell lymphomamaintenance therapysurvival

Identifiers

PMID42015349
PMCPMC13108342

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.